Session

IBD (Posters)

PILLCAM CROHN'S CAPSULE - THE USE OF A PANENTERIC CAPSULE ENDOSCOPY IN A PORTUGUESE CENTER
PILLCAM CROHN'S CAPSULE - THE USE OF A PANENTERIC CAPSULE ENDOSCOPY IN A PORTUGUESE CENTER

IBD (Posters)  et al.

COVID-19 OUTBREAK IMPACTING QUALITY OF LIFE AND SELF-PERCEIVED STRESS IN INFLAMMATORY BOWEL DISEASE
COVID-19 OUTBREAK IMPACTING QUALITY OF LIFE AND SELF-PERCEIVED STRESS IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

DIAGNOSTIC AND PROGNOSTIC VALUES OF ANTI-GLYCOPROTEIN 2 ANTIBODIES (GP2A) IN INFLAMMATORY BOWEL DISEASES: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY
DIAGNOSTIC AND PROGNOSTIC VALUES OF ANTI-GLYCOPROTEIN 2 ANTIBODIES (GP2A) IN INFLAMMATORY BOWEL DISEASES: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY

IBD (Posters)  et al.

INCREASED RELAPSE RATE AFTER DISCONTINUATION OF IMMUNOMODULATOR MONOTHERAPY BUT NOT AFTER WITHDRAWAL FROM COMBINATION REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
INCREASED RELAPSE RATE AFTER DISCONTINUATION OF IMMUNOMODULATOR MONOTHERAPY BUT NOT AFTER WITHDRAWAL FROM COMBINATION REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

IBD (Posters)  et al.

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES
SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES

IBD (Posters)  et al.

RISK FACTORS FOR POOR POSTOPERATIVE OUTCOME IN PATIENTS WITH CROHN'S DISEASE UNDERGOING ILEOCECAL RESECTION
RISK FACTORS FOR POOR POSTOPERATIVE OUTCOME IN PATIENTS WITH CROHN'S DISEASE UNDERGOING ILEOCECAL RESECTION

IBD (Posters)  et al.

PREVALENCE AND PREDICTIVE FACTORS OF FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION
PREVALENCE AND PREDICTIVE FACTORS OF FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION

IBD (Posters)  et al.

POST-OPERATIVE COURSE OF CROHN´S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY
POST-OPERATIVE COURSE OF CROHN´S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY

IBD (Posters)  et al.

GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINIC EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL
GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINIC EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL

IBD (Posters)  et al.

IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY
IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY

IBD (Posters)  et al.

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

IBD (Posters)  et al.

INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION
INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION

IBD (Posters)  et al.

INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS
INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS

IBD (Posters)  et al.

COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT
COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT

IBD (Posters)  et al.

TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT
TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT

IBD (Posters)  et al.

NEW DIAGNOSTIC CAPABILITIES FOR CROHN´S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM
NEW DIAGNOSTIC CAPABILITIES FOR CROHN´S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM

IBD (Posters)  et al.

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

IBD (Posters)  et al.

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

Item 201 - 220 / 279
1 2 3 4 5 6 7 8 9 10
11
12 13 14